This week, Acadia Pharmaceuticals announced the initiation of its Phase 3 COMPASS PWS study! This study focuses on evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for treating hyperphagia in Prader-Willi syndrome. The COMPASS PWS trial is a 12-week, double-blind, randomized, placebo-controlled global Phase 3 trial, with approximately 170 participants aged five to 30 years.
Stay tuned for updates as we eagerly anticipate the Phase 3 trial outcomes and the potential for a groundbreaking treatment option for those living with PWS. Learn more about the COMPASS PWS study at the buttons below.